





## Clinical Disease Measures in Generalized Pustular Psoriasis

A. David Burden, Siew Eng Choon, Alice B. Gottlieb, Alexander Navarini, Richard B. Warren

American Journal of Clinical Dermatology, 2021. DOI: 10.1007/s40257-021-00653-0

Accurate assessment of generalized pustular psoriasis (GPP) disease severity and treatment outcomes is essential for providing effective patient care and for the development and evaluation of novel therapies

## A number of disease measures...

Physician Global Assessment (PGA)



Measures disease severity on a 7-point scale Psoriasis Area and Severity Index (PASI)



Measures redness, thickness and scaling

Clinical Global Impression (CGI) scale



Clinician's view of patient's global function before and after treatment Japanese Dermatological Association severity index of GPP (JDA-GPPSI)



Measures skin symptoms, systemic symptoms, laboratory findings, and disease severity

## ...and patient reported outcomes...

Psoriasis symptom scale (PSS)



Measures pain, redness, itching, and burning Pain visual analog scale (Pain VAS)



Measures pain severity

Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue



Assesses self-reported fatigue and impact on daily living

Dermatology Quality of Life Index (DLQI)



Measures health-related quality of life

...are used in the assessment of GPP, but most have been adopted from other diseases. New GPP-specific clinical disease measures are emerging...

Generalized Pustular Psoriasis Physician Global Assessment (GPPGA)



Physician-based assessment of severity of pustules, erythema, and scaling of GPP lesions Generalized Pustular Psoriasis Area and Severity Index (GPPASI)



Modification of the PASI score, with the induration component replaced by a pustule component

## ...but these require clinical validation

The infographic represents the opinion of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online.